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Patients affected by polycythemia vera (PV), a myeloproliferative neoplasm characterized by an elevated red blood cell mass, are
at high risk of vascular and thrombotic complications. Conventional therapeutic options aim at reducing vascular and thrombotic
risk; low-dose aspirin and phlebotomy are first-line recommendations, for patients at low risk of thrombotic events, whereas
cytoreductive therapy, usually hydroxyurea (HU) or interferon alpha, is recommended for high-risk patients. In the present study,
we report the case of a patient with persistent oral ulcerations, possibly related to long-lasting HU treatment, firstly treated with
topic and systemic corticosteroids and thenmore effectively with the addition of low-level laser therapy. Laser photobiomodulation
has achieved pain control and has contributed to the healing of oral ulcers without any adverse effect; this has permitted a reduction
in the dose of systemic corticosteroids and the suspension of the use of the topic ones, due to the long-term stability of oral health,
even after the interruption of low-level laser therapy sessions.
1. Introduction
Patients affected by polycythemia vera (PV), a myeloprolif-
erative neoplasm characterized by an elevated red blood cell
mass, are at high risk of vascular and thrombotic complica-
tions; they also have reduced quality of life due to a substantial
symptom burden that includes pruritus, fatigue, constitu-
tional symptoms, microvascular disturbances, and bleeding.
Conventional therapeutic options aim at reducing vascular
and thrombotic risk; low-dose aspirin and phlebotomy are
first-line recommendations, for patients at low risk of throm-
botic events, whereas cytoreductive therapy, usually hydrox-
yurea (HU) or interferon alpha, is recommended for high-
risk patients [1].
Mucocutaneous ulcers are possible complicating adverse
effects caused by HU; these lesions can appear right after the
beginning of HU therapy or can be a later effect, with similar
clinical presentation in both situations. The oral alterations
are uncommon, but they could have a greater clinical impact
because of severe pain and feeding or speaking impairment
[2, 3].
Data from literature suggest that oral ulceration is the first
occurring oral side effect of hydroxyurea, usually developing
after a variable period of time since administration, ranging
between 5 months and up to 3 years. Mucocutaneous lesions
have been diagnosed in 167 of 3411 patients on hydroxyurea
with Philadelphia-chromosome-negative chronic myelopro-
liferative neoplasms in a large Italian cohort [4]; of this sub-
group, 27 patients presented oral ulcerations. Almost half of
these patients needed to discontinue hydroxyurea with reso-
lution of lesions in about one month. The remaining patients
received local therapy, consisting of mouthwash with folic
acid and vitamin A, and they obtained some symptomatic
improvement. However, complete healing was achieved only
after HU dose reduction or suspension in an average time
frame of three months.
Other studies [5, 6] have reported 12.5% to 13%prevalence
of mucocutaneous involvement in smaller cohorts of 40 and
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Figure 1: Erosive lesions presented in (a) and (b) lateral border of the tongue.
158 patients, respectively, including mucosal symptoms, such
as pain and burning sensation, atrophy, and ulcers.
Actually, dose reduction or suspension of HU, if possible,
can be considered as the most effective available measure [2,
4–6].
In the present study, we report the case of a patient
with persistent oral ulcerations, possibly related to long-last-
ing HU treatment, firstly treated with topic and systemic cor-
ticosteroids and then more effectively with the addition of
low-level laser therapy.
2. Case Presentation
A 72-year-old male (diagnosed with PV in 1994 and treated
with HU since 1995) was referred to the Oral Medicine Sec-
tion of the Turin University in March 2014 because of severe
tongue and lips pain and difficulty in feeding and speaking.
At the time being, HU dosage consisted of three 500mg
tablets daily. At physical examination, extensive ulcerations
on the tongue and lips were observed (Figure 1). Based on
the clinical appearance and the topography of the lesions, a
differential diagnosis between HU related ulcers and erosive
lichen was posed. However, advice against the execution of
the oral biopsy came directly from the oncologist, due to the
very high level of platelets (more than 1.000.000/𝜇L) detected
in the patient’s blood.
Due to the impossibility of solving the diagnostic
dilemma through histopathological examination, we opted
for an ex juvantibus approach and proceeded to administer
an appropriate therapywith the intention of improving at first
the patient’s quality of life.
In agreement with the oncologist, a combined treatment
with systemic (oral administration of 75mg of prednisone
daily) and topic corticosteroids (clobetasol 0.05% ointment
twice daily) was established. During the following two
months, a reduction of symptoms and oral lesions allowed
a therapy reduction to 12.5mg daily of prednisone, with the
topic treatment being unchanged.
After a short period of relative wellness, in July 2014 the
oral situation worsened again, with diffuse extensive oral
ulcerations, high levels of pain, and very poor quality of
life, although HU dosage had been unaltered since our first
encounter with the patient, four months before. Therapy was
modified again: 75mg of prednisone daily was administered
for two weeks and then, in accordance with the oncologist,
dosage was reduced to 50mg daily, but with no reduction
of symptoms and pain; tacrolimus ointment (Protopic 0.1%
ointment) was used instead of topical clobetasol, but this was
to no avail.
In September 2014, the decision was taken to add photo-
biomodulation (low-level laser therapy, LLLT) to the phar-
macological therapy, with a twice-weekly frequency. A diode
laser (GaAlAs) 810 nm (Ora-Laser D-LightORALIAMedical
GmbH,Germany)was used, with spot size 1.3 cm2, power set-
ting 100mW, mean power 50mW, duty cycle 50%, frequency
10.000Hz, fluence 6 J/cm2 (calculated as follows: Fluence =
power × time/surface), treatment time 160 seconds, point by
point technique, not in contact (distance to themucosa about
2mm) perpendicular to the treatment area.
Noncontact mode was specifically chosen in order to
prevent the onset of additional pain which could be obtained
had we preferred the direct contact between the laser probe
and the oral ulcers undergoing the LLLT treatment.
After 2 weeks, a marked improvement was immediately
observed with disappearance of pain and the beginning of
reepithelialization of the mucosa; at that time, HU dosage
consisted of three 500mg tablets daily interchangedwith four
500mg tablets every other day.
However, due to hospital admission for pulmonary com-
plications, LLLT had to be suspended for 2 months, together
with a gradual reduction of prednisone dosage until complete
suspension: inevitably, the interruption of these treatments
caused a worsening of the oral clinical situation.
After another 4 weeks of photobiomodulation treatment
sessions, the lesions had not disappeared completely, but
a significant reduction of pain was observed. Due to the
improvement of the oral condition, the decision was taken to
stop topic corticosteroid treatment continuing with systemic
treatment and laser therapy, and the remission of the lingual
lesions was obtained.
After another 3 weeks, symptoms and mucosal lesions
disappearance, together with functional recovery, were
observed (Figure 2).
Since then, photobiomodulation treatment was conclu-
ded, together with the gradual reduction of systemic corticos-
teroid treatment in the following months. In the meantime,
Case Reports in Dentistry 3
(a) (b)
(c)
Figure 2: (a–c) Complete disappearance of the erosive tongue lesion at the end of the treatment provided.
HU dosage had been maintained, at the aforementioned
dosage of three to four 500mg tablets every other day.
In September 2015, HU was finally substituted with
JACAVI; since then, the patient continued to be ulcers-free;
ad libitum application of topical corticosteroidwas prescribed
to the patient but has never been used. Our last follow-up
visit, conducted in July 2016, showed no signs or symptoms
at the oral cavity; meanwhile, prednisone was furthermore
reduced to a minimum of 5mg every other day.
3. Discussion
PV is a classic Philadelphia-chromosome-negativemyelopro-
liferative neoplasm (MPN), characterized primarily by an
increase in red blood cell mass together with an excessive
proliferation of myeloid and megakaryocytic components in
the bonemarrow, resulting in high red blood cells and platelet
and white blood cells counts.
In the past 10 years, the pathophysiology of this condition
has been defined as JAK/STAT pathway activation, almost
always due to mutations in JAK2 exon 12 or 14 (JAK2 V617F)
[4]. These findings have become indicative not only for diag-
nosis, so much that the presence of the JAK2 V617Fmutation
has been introduced as a major criterion in the diagnosis
of PV since 2008, but also for treatment, most recently cul-
minating in the approval of JAK inhibitors as an alternative
for patients who are resistant or intolerant to HU [1].
Dresler and Stein described the synthesis of HU in 1869;
the antitumor activity of this drug was reported in the
1960s, when it was tested against mouse leukemia and other
malignancies. In the 1990s, HU was described as an inhibitor
of ribonucleotide reductase, an enzyme involved in the syn-
thesis of deoxyribonucleotides: by depleting the pool of deo-
xyribonucleotides, HU inhibits DNA synthesis, arresting the
cell cycle at the G1/S phase [7].
On the other hand, skin and mucosal side effects are not
completely understood and usually occur following long-
term therapy; cutaneous abnormalities include xerosis, ich-
thyosiform lesions, dark brown pigmentation of skin folds
and nails, and malleolar ulcers as well as malignant tumors
[8–10].
Oral lesions are rare complications that can rapidly
develop right after the start of the therapy [2] or as the side
effect of a long-term exposure [3]; they often appear as painful
ulcers, sometimes associated with skin lesions. Glossitis and
stomatitis with intense erythemamay also be observed [6, 11].
According to literature, there is no specific protocol for
management ofHUoral ulcers, apart from the dose reduction
or suspension of HU itself. In the largest cohort of patients
undergoing HU, a mouthwash containing folic acid and vita-
min A was prescribed, obtaining symptomatic improvement;
however, no details regarding the methods (dosage, timing,
etc.) are reported;moreover, the authors declared that healing
was achieved only after HU dose reduction or suspension in
an average time frame of three months [4].
To our knowledge, only two cases of oral cancer following
long-term treatment with HU have been reported [12, 13].
Therapeutic use of laser light was introduced in 1966,
when Endre Mester published the first scientific article con-
cerning stimulating and nonthermal effects of ruby laser on
mice skin [14].
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The energy of certain wavelengths (635–1100 nm) is
absorbed by photoacceptor chromophores in the respiratory
chain (cytochrome c oxidase) in mitochondria: this results
in a change in the redox status of the cell, together with an
increase in ATP production and cell proliferation rate [15–
17], thanks to the activation of the nucleic acids, proteins, and
enzymes regulation paths. It also participates in the regula-
tion of the level of cytokines and growth factors and inflam-
mation and tissue oxygenation mediators.
These biochemical cell changes lead to advantages as an
increase in the speed of wound healing and a marked anal-
gesic effect [15–18].
The rationale of using photobiomodulation is related to
the possibility of accelerating the healing process of ongoing
oral ulcers, as shown and reported by several studies [19–22].
In this case report laser photobiomodulation has achieved
pain control and has contributed to the healing of oral ulcers
without any adverse effect; this has permitted a reduction in
the dose of systemic corticosteroids and the suspension of the
use of the topic ones, due to the long-term stability of oral
health, even after the interruption of LLLT sessions.
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